|
US4754065A
(en)
|
1984-12-18 |
1988-06-28 |
Cetus Corporation |
Precursor to nucleic acid probe
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
|
GB8611832D0
(en)
|
1986-05-15 |
1986-06-25 |
Holland I B |
Polypeptide
|
|
US5037743A
(en)
|
1988-08-05 |
1991-08-06 |
Zymogenetics, Inc. |
BAR1 secretion signal
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6011138A
(en)
|
1997-02-20 |
2000-01-04 |
Idec Pharmaceuticals Corporation |
Gamma-1 anti-human CD23 monoclonal antibodies
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
HK1052372A1
(zh)
|
2000-02-24 |
2003-09-11 |
Xcyte Therapies, Inc. |
细胞的同步刺激和富集
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7446179B2
(en)
|
2000-11-07 |
2008-11-04 |
City Of Hope |
CD19-specific chimeric T cell receptor
|
|
CA2436180C
(en)
|
2001-01-31 |
2011-11-08 |
Idec Pharmaceutical Corporation |
Immunoregulatory antibodies and uses thereof
|
|
AU2002368077B2
(en)
|
2001-07-12 |
2010-03-04 |
Jefferson Foote |
Super humanized antibodies
|
|
PT1731605E
(pt)
|
2004-03-31 |
2010-04-14 |
Int Inst Cancer Immunology Inc |
Péptidos antigénicos de cancro derivados de wt1
|
|
CA2793753C
(en)
|
2010-03-26 |
2018-06-05 |
Memorial Sloan-Kettering Cancer Center |
Antibodies to muc16 and methods of use thereof
|
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
|
JP6285553B2
(ja)
|
2013-08-26 |
2018-02-28 |
インノバイオファーム リミテッド |
抗cd30キメラ抗原受容体およびその使用
|
|
WO2015130766A1
(en)
|
2014-02-25 |
2015-09-03 |
Memorial Sloan-Kettering Cancer Center |
Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
|
|
JP6831777B2
(ja)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Cd33キメラ抗原受容体を使用する癌の処置
|
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
GB201413335D0
(en)
|
2014-07-28 |
2014-09-10 |
Azotic Technologies Ltd |
Agricultural methods
|
|
RU2017102769A
(ru)
|
2014-07-29 |
2018-08-28 |
Пфайзер Инк. |
EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА
|
|
US20160208018A1
(en)
|
2015-01-16 |
2016-07-21 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
|
EP3250602A1
(en)
|
2015-01-26 |
2017-12-06 |
Cellectis |
T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
|
|
WO2016142532A1
(en)
|
2015-03-11 |
2016-09-15 |
Cellectis |
Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
|
|
KR102618312B1
(ko)
|
2015-03-17 |
2023-12-28 |
메모리얼 슬로안 케터링 캔서 센터 |
항muc16 항체 및 그의 용도
|
|
TWI700298B
(zh)
|
2015-04-13 |
2020-08-01 |
美商輝瑞股份有限公司 |
靶向b細胞成熟抗原之嵌合型抗原受體類
|
|
TW201702272A
(zh)
|
2015-05-22 |
2017-01-16 |
美國紀念斯隆 凱特琳癌症中心 |
Prame肽專一性類t細胞受體抗體
|
|
CA2994746A1
(en)
|
2015-08-11 |
2017-02-16 |
Cellectis |
Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
JP2018531014A
(ja)
|
2015-10-15 |
2018-10-25 |
アメリカ合衆国 |
抗cd30キメラ抗原受容体
|
|
CN122146606A
(zh)
|
2015-11-04 |
2026-06-05 |
菲特治疗公司 |
用于诱导造血细胞分化的方法和组合物
|
|
WO2017093969A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
BR112018014585A2
(pt)
|
2016-01-21 |
2018-12-11 |
Pfizer |
receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii
|
|
AU2017240801A1
(en)
|
2016-04-01 |
2018-10-25 |
Amgen Inc. |
Chimeric receptors to FLT3 and methods of use thereof
|
|
CN109641037B
(zh)
|
2016-04-13 |
2022-09-06 |
西安奥瑞单抗生物技术有限公司 |
抗psma抗体及其用途
|
|
WO2018006882A1
(zh)
|
2016-07-08 |
2018-01-11 |
科济生物医药(上海)有限公司 |
抗密蛋白18a2的抗体及其应用
|
|
JP7231158B2
(ja)
|
2016-10-19 |
2023-03-01 |
ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント |
Cd133結合剤およびその使用
|
|
CN108395482B
(zh)
|
2017-02-08 |
2021-02-05 |
西比曼生物科技(香港)有限公司 |
一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
|
|
EP3583129B1
(en)
|
2017-02-14 |
2021-11-03 |
Kite Pharma, Inc. |
Cd70 binding molecules and methods of use thereof
|
|
BR112019023608A2
(pt)
*
|
2017-05-12 |
2020-05-26 |
Crispr Therapeutics Ag |
Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
|
|
PE20241587A1
(es)
|
2017-06-02 |
2024-08-01 |
Pfizer |
Receptores de antigenos quimericos que se dirigen a flt3
|
|
KR20230008269A
(ko)
|
2017-08-07 |
2023-01-13 |
엔비이-테라퓨틱스 아게 |
생체 내 내성이 높은 항체 약물 결합체
|
|
CN111556892A
(zh)
*
|
2017-12-08 |
2020-08-18 |
菲特治疗公司 |
使用增强的iPSC衍生的效应细胞的免疫疗法
|
|
MX2020008184A
(es)
|
2018-02-01 |
2020-09-22 |
Pfizer |
Receptores de antigeno quimericos dirigidos a cd70.
|
|
CN116836297A
(zh)
|
2018-04-12 |
2023-10-03 |
上海赛比曼生物科技有限公司 |
靶向bcma的嵌合抗原受体及其制法和应用
|
|
JP7584127B2
(ja)
|
2018-04-26 |
2024-11-15 |
ベイラー カレッジ オブ メディスン |
活性化された病原性t細胞およびnk細胞の選択的標的化のための自己/同種免疫防御受容体
|
|
KR102351623B1
(ko)
|
2018-05-14 |
2022-01-14 |
주식회사 엘지에너지솔루션 |
분리막 기재가 없는 분리막
|
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
WO2020005837A1
(en)
|
2018-06-25 |
2020-01-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of nkg2d chimeric antigen receptor t cells for controlling triple-negative breast cancer
|
|
AU2019299555A1
(en)
|
2018-07-04 |
2021-02-25 |
Cytoimmune Therapeutics, Inc. |
Compositions and methods for immunotherapy targeting FLT3, PD-1, and/or PD-L1
|
|
US12036242B2
(en)
|
2018-07-05 |
2024-07-16 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
CAR T cells that target B-cell antigens
|
|
SG11202100838QA
(en)
|
2018-07-26 |
2021-02-25 |
Tcr2 Therapeutics Inc |
Compositions and methods for tcr reprogramming using target specific fusion proteins
|
|
US12378572B2
(en)
|
2018-09-07 |
2025-08-05 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
EA202191257A1
(ru)
|
2018-11-07 |
2021-12-06 |
Криспр Терапьютикс Аг |
Противораковая терапия на основе иммуноцитов, связывающих liv1
|
|
CN109468284A
(zh)
|
2018-11-30 |
2019-03-15 |
北京美康基免生物科技有限公司 |
一种基于cd19和psma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
|
|
JP2022510207A
(ja)
*
|
2018-12-02 |
2022-01-26 |
フェイト セラピューティクス,インコーポレイテッド |
増強されたiPSC派生エフェクター細胞を使用した免疫療法
|
|
KR20250116790A
(ko)
|
2018-12-12 |
2025-08-01 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체 및 car-t 세포 및 사용 방법
|
|
CN109680002A
(zh)
|
2019-01-09 |
2019-04-26 |
上海怡豪生物科技有限公司 |
联合msln单链抗体和ccl19杀伤胃癌细胞的car载体及其构建方法和应用
|
|
CN109628492A
(zh)
|
2019-01-09 |
2019-04-16 |
上海怡豪生物科技有限公司 |
联合MSLN单链抗体和PD-1mAb杀伤胃癌细胞的CAR载体及其构建方法和应用
|
|
KR20210116526A
(ko)
|
2019-01-16 |
2021-09-27 |
빔 테라퓨틱스, 인크. |
증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포
|
|
PT3749338T
(pt)
|
2019-01-16 |
2024-09-20 |
Caribou Biosciences Inc |
Anticorpo de bcma humanizado e células bcma-car-t
|
|
US11738050B2
(en)
|
2019-02-01 |
2023-08-29 |
Regents Of The University Of Minnesota |
Compounds binding to fibroblast activation protein alpha
|
|
MX2021010441A
(es)
|
2019-03-01 |
2021-09-21 |
Allogene Therapeutics Inc |
Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
|
|
WO2020186204A1
(en)
|
2019-03-13 |
2020-09-17 |
Ulmert Hans David Staffan |
Prame binding molecules and uses thereof
|
|
CN113906133A
(zh)
*
|
2019-04-11 |
2022-01-07 |
菲特治疗公司 |
工程改造的iPSC和免疫效应细胞中的CD3重建
|
|
BR112021022666A2
(pt)
|
2019-05-14 |
2022-03-29 |
Werewolf Therapeutics Inc |
Frações de separação e seus métodos e uso
|
|
CA3147122A1
(en)
|
2019-07-12 |
2021-01-21 |
Futuregen Biopharmaceutical (Beijing) Co., Ltd. |
Cldn18.2 antibody and use thereof
|
|
KR20220035190A
(ko)
|
2019-07-17 |
2022-03-21 |
페이트 세러퓨틱스, 인코포레이티드 |
면역 효과기 세포 조작 및 이의 용도
|
|
CN111363046A
(zh)
|
2020-03-11 |
2020-07-03 |
深圳宾德生物技术有限公司 |
靶向nkg2d的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
|